两种新药在治疗小细胞肺癌方面显示出可喜的成果,为病人带来了希望。 Two new drugs show promising results in treating small cell lung cancer, offering hope for patients.

一种新的药物(Ifinatamab deruxtecan)在治疗曾接受化疗的大阶段小型细胞肺癌患者方面显示出有希望的成果。 A new drug, ifinatamab deruxtecan, showed promising results in treating patients with extensive-stage small cell lung cancer who had previously received chemotherapy. 在第二阶段试验中,该药物的响应率达到48.2%,疾病控制率达到87.6%,中位存活率为10.3个月。 In a Phase 2 trial, the drug achieved a 48.2% response rate and an 87.6% disease control rate, with a median survival of 10.3 months. 治疗有可控的副作用, 美国食品和药物管理局授予它突破性的治疗地位. The treatment had manageable side effects, and the FDA granted it breakthrough therapy status. 另一种药物,SHR-4849,在早期试验中也显示出积极的成果,在复发小细胞肺癌的患者中,答复率为59.5%,疾病控制率为90.5%。 Another drug, SHR-4849, also showed positive results in early trials, with a 59.5% response rate and 90.5% disease control rate in patients with relapsed small cell lung cancer. 这两种治疗为一种治疗选择有限的疾病提供了新的希望。 Both treatments offer new hope for a disease that has limited treatment options.